Production of Nα-acetyl Tα1-HSA through in vitro acetylation by RimJ
Thymosin alpha 1 (Tα1) is an important immunomodulating agent with various clinical applications. The natural form of Tα1 is Nα -acetylated, which was supposed to be related to in vivo stability of the hormone. In this study, fusion protein Tα1-HSA was constructed and expressed in Pichia pastoris. RimJ, a Nα -acetyltransferase from E.coli, was also overexpressed and purified to homogeneity. In vitro acetylation of Tα1-HSA in the presence of RimJ and acetyl coenzyme A resulted in Nα -acetyl Tα1-HSA. The Nα -acetylation was determined by LC-MS/MS. Kinetic assay indicated that RimJ had a higher affinity to desacetyl Tα1 than to Tα1-HSA. Bioactivity assay revealed fully retained activity of Tα1 when the hormone was connected to the N-terminus of the fusion protein, while the activity was compromised in our previously constructed HSA-Tα1. With fully retained activity and N-terminal acetylation, Nα -acetyl Tα1-HSA was expected to be a more promising pharmaceutical agent than Tα1.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2017 |
---|---|
Erschienen: |
2017 |
Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
---|---|
Enthalten in: |
Oncotarget - 8(2017), 56 vom: 10. Nov., Seite 95247-95255 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Chen, Jing [VerfasserIn] |
---|
Links: |
---|
Themen: |
Acetylation |
---|
Anmerkungen: |
Date Revised 20.11.2019 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.18632/oncotarget.20259 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM278860575 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM278860575 | ||
003 | DE-627 | ||
005 | 20231225021618.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2017 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.18632/oncotarget.20259 |2 doi | |
028 | 5 | 2 | |a pubmed24n0929.xml |
035 | |a (DE-627)NLM278860575 | ||
035 | |a (NLM)29221124 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Chen, Jing |e verfasserin |4 aut | |
245 | 1 | 0 | |a Production of Nα-acetyl Tα1-HSA through in vitro acetylation by RimJ |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 20.11.2019 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Thymosin alpha 1 (Tα1) is an important immunomodulating agent with various clinical applications. The natural form of Tα1 is Nα -acetylated, which was supposed to be related to in vivo stability of the hormone. In this study, fusion protein Tα1-HSA was constructed and expressed in Pichia pastoris. RimJ, a Nα -acetyltransferase from E.coli, was also overexpressed and purified to homogeneity. In vitro acetylation of Tα1-HSA in the presence of RimJ and acetyl coenzyme A resulted in Nα -acetyl Tα1-HSA. The Nα -acetylation was determined by LC-MS/MS. Kinetic assay indicated that RimJ had a higher affinity to desacetyl Tα1 than to Tα1-HSA. Bioactivity assay revealed fully retained activity of Tα1 when the hormone was connected to the N-terminus of the fusion protein, while the activity was compromised in our previously constructed HSA-Tα1. With fully retained activity and N-terminal acetylation, Nα -acetyl Tα1-HSA was expected to be a more promising pharmaceutical agent than Tα1 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a RimJ | |
650 | 4 | |a acetylation | |
650 | 4 | |a bioactivity | |
650 | 4 | |a human serum albumin | |
650 | 4 | |a thymosin alpha 1 | |
700 | 1 | |a Li, Haibin |e verfasserin |4 aut | |
700 | 1 | |a Wang, Tao |e verfasserin |4 aut | |
700 | 1 | |a Sun, Shuyang |e verfasserin |4 aut | |
700 | 1 | |a Liu, Jia |e verfasserin |4 aut | |
700 | 1 | |a Chen, Jianhua |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 8(2017), 56 vom: 10. Nov., Seite 95247-95255 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
773 | 1 | 8 | |g volume:8 |g year:2017 |g number:56 |g day:10 |g month:11 |g pages:95247-95255 |
856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.20259 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 8 |j 2017 |e 56 |b 10 |c 11 |h 95247-95255 |